IO Biotech 8-K: Exit/Disposal Costs Reported
Ticker: IOBT · Form: 8-K · Filed: Sep 29, 2025 · CIK: 1865494
| Field | Detail |
|---|---|
| Company | Io Biotech, Inc. (IOBT) |
| Form Type | 8-K |
| Filed Date | Sep 29, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1.0 million, $1.5 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: restructuring, disposal, regulatory
TL;DR
IO Biotech filing shows exit/disposal costs, might be winding down.
AI Summary
IO Biotech, Inc. filed an 8-K on September 29, 2025, reporting on events as of September 25, 2025. The filing indicates costs associated with exit or disposal activities, a Regulation FD disclosure, and other events, including financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Copenhagen, Denmark.
Why It Matters
This filing signals potential restructuring or winding down activities for IO Biotech, which could impact its ongoing operations and future prospects.
Risk Assessment
Risk Level: medium — The filing indicates costs associated with exit or disposal activities, suggesting potential financial distress or strategic shifts.
Key Players & Entities
- IO Biotech, Inc. (company) — Registrant
- September 25, 2025 (date) — Earliest event date
- September 29, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Copenhagen, Denmark (location) — Principal executive offices
- + 45 7070 2980 (phone_number) — Registrant's telephone number
FAQ
What specific 'exit or disposal activities' is IO Biotech undertaking?
The filing does not specify the exact nature of the 'Cost Associated with Exit or Disposal Activities' beyond listing it as an item of disclosure.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on September 25, 2025.
What is IO Biotech's primary business sector?
IO Biotech, Inc. is in the Pharmaceutical Preparations sector, with SIC code 2834.
Where are IO Biotech's principal executive offices located?
IO Biotech's principal executive offices are located at Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark.
What is the SEC file number for IO Biotech?
The SEC file number for IO Biotech, Inc. is 001-41008.
Filing Stats: 851 words · 3 min read · ~3 pages · Grade level 10.7 · Accepted 2025-09-29 07:17:59
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share IOBT The Nasdaq Stock Mar
- $1.0 million — xpenditures in a range of approximately $1.0 million to $1.5 million, primarily related to e
- $1.5 m — range of approximately $1.0 million to $1.5 million, primarily related to employee wa
Filing Documents
- d940102d8k.htm (8-K) — 28KB
- d940102dex991.htm (EX-99.1) — 16KB
- g940102g0929041325520.jpg (GRAPHIC) — 3KB
- 0001193125-25-221704.txt ( ) — 167KB
- iobt-20250925.xsd (EX-101.SCH) — 3KB
- iobt-20250925_lab.xml (EX-101.LAB) — 17KB
- iobt-20250925_pre.xml (EX-101.PRE) — 11KB
- d940102d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 IO Biotech, Inc. Press Release, dated as of September 29, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IO BIOTECH, INC. Date: September 29, 2025 By: /s/ Mai-Britt Zocca, Ph.D. Name: Mai-Britt Zocca, Ph.D. Title: Chief Executive Officer